Dendritic cells (DCs) are professional antigen presenting cells (APCs) that both initiate and modulate the immune response. DCs are cells in the pathway of antigen capture and presentation to T cells, with the unique ability to directly prime naïve CD4+ and CD8+ T cells.

A study (doi:10.1016/j.clim.2008.07.027) published by Elsevier this month in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method that facilitates the induction of a specific type of immune suppressive cells, called 'regulatory T cells' for therapeutic use.

Argos Therapeutics and Université de Montréal today announced the presentation of new information on Argos'process for developing dendritic cell-based immunotherapies for HIV.

Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.

Members and Friends of CareToLive took to the streets in 10 cities across America on May 30, 2008. Why? To continue to tell the story about how some folks at the FDA were busy serving themselves when they were supposed to be serving the people of this great nation. To continue to tell the story about how 30,000 men, today, are in desperate need of a treatment for their prostate cancer, and how the FDA wrongly denied them some help.

Specific immune therapy works for many people and it is becoming increasingly popular in Europe, according to the German Institute for Quality and Efficiency in Health Care.